Will you incorporate immunotherapy in neoadjuvant treatment of triple negative breast cancer based off KEYNOTE-522?
3
2 Answers
Mednet Member
Medical Oncology · Baptist Health South Florida
Insurance issues aside, I would incorporate immunotherapy into neoadjuvant triple negative therapy. I participated in this trial and I am aware of the pathologic complete response data. I suspect that this could lead, ultimately, to FDA approval. In the meantime, if feasible, I would use the Keynote...